MedPath

Eleclazine

Generic Name
Eleclazine
Drug Type
Small Molecule
Chemical Formula
C21H16F3N3O3
CAS Number
1443211-72-0
Unique Ingredient Identifier
PUY08529FK
Background

Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic Heart Disease, Ventricular Arrhythmia, and Long QT Syndrome Type 3, among others.

Clinical Trials
Related News

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

Phase 1
Completed
Conditions
Long QT Syndrome
Interventions
First Posted Date
2015-05-12
Last Posted Date
2015-12-22
Lead Sponsor
Gilead Sciences
Target Recruit Count
55
Registration Number
NCT02441829

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

Phase 1
Completed
Conditions
Long QT Syndrome
Interventions
First Posted Date
2015-04-08
Last Posted Date
2019-07-29
Lead Sponsor
Gilead Sciences
Target Recruit Count
49
Registration Number
NCT02412098

GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease

Phase 2
Withdrawn
Conditions
Ischemic Heart Disease
Interventions
Drug: Placebo
First Posted Date
2015-03-03
Last Posted Date
2015-06-08
Lead Sponsor
Gilead Sciences
Registration Number
NCT02377336

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

Phase 1
Completed
Conditions
Long QT Syndrome
Interventions
Drug: Placebo to match GS-6615
Drug: Placebo to match dofetilide
First Posted Date
2015-02-19
Last Posted Date
2015-05-20
Lead Sponsor
Gilead Sciences
Target Recruit Count
60
Registration Number
NCT02365532
Locations
🇺🇸

Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States

Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome

Phase 1
Completed
Conditions
LQT2 Syndrome
Interventions
Drug: Placebo
First Posted Date
2015-02-19
Last Posted Date
2020-12-30
Lead Sponsor
Gilead Sciences
Target Recruit Count
13
Registration Number
NCT02365506
Locations
🇺🇸

University of Rochester Medical Center/Strong Memorial Hospital, Rochester, New York, United States

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

Phase 3
Terminated
Conditions
Long QT Syndrome Type 3
Interventions
First Posted Date
2014-11-25
Last Posted Date
2018-01-12
Lead Sponsor
Gilead Sciences
Target Recruit Count
41
Registration Number
NCT02300558
Locations
🇨🇦

Nova Scotia Health Authority, Halifax, Nova Scotia, Canada

🇫🇷

Groupe Hospitalier Bichat Claude Bernard, Paris, France

🇫🇷

CHU Réunion Sud, Saint-Pierre, France

and more 9 locations

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

Phase 2
Terminated
Conditions
Hypertrophic Cardiomyopathy
Interventions
Drug: Placebo
First Posted Date
2014-11-14
Last Posted Date
2018-09-24
Lead Sponsor
Gilead Sciences
Target Recruit Count
172
Registration Number
NCT02291237
Locations
🇮🇹

Azienda Ospedaliera San Camillo Forlanini, Rome, Italy

🇳🇱

Academisch Medisch Centrum Amsterdam, Amsterdam, Noord-Holland, Netherlands

🇮🇹

Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

and more 43 locations

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator

Phase 2
Completed
Conditions
Ventricular Arrhythmia
Interventions
Drug: Placebo to match eleclazine
First Posted Date
2014-04-04
Last Posted Date
2019-04-09
Lead Sponsor
Gilead Sciences
Target Recruit Count
313
Registration Number
NCT02104583
Locations
🇺🇸

Cardiovascular Associates of Mesa, Mesa, Arizona, United States

🇺🇸

Ohiohealth Corporation, Columbus, Ohio, United States

🇺🇸

Charlotte Heart and Vascular Institute, Port Charlotte, Florida, United States

and more 81 locations

Study of the Effect of GS-6615 in Subjects With LQT-3

Phase 1
Completed
Conditions
Long QT Syndrome
Interventions
First Posted Date
2013-05-08
Last Posted Date
2014-11-17
Lead Sponsor
Gilead Sciences
Target Recruit Count
24
Registration Number
NCT01849003
Locations
🇺🇸

University of Rochester Medical Center/Strong Memorial Hospital, Rochester, New York, United States

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

Phase 1
Completed
Conditions
Ischemic Heart Disease
Interventions
Drug: Placebo
First Posted Date
2013-05-06
Last Posted Date
2013-11-13
Lead Sponsor
Gilead Sciences
Target Recruit Count
36
Registration Number
NCT01847391
Locations
🇺🇸

Investigational Site, Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy